Company overview
CARB-X is a global non-profit partnership that accelerates the development of antibacterial products to combat drug-resistant bacteria. The organization provides non-dilutive funding, scientific expertise, regulatory guidance, and business support to developers of new antibiotics, preventatives, rapid diagnostics, and related products. CARB-X maintains the world's most scientifically diverse early-stage pipeline, supporting projects from basic research through Phase 1 clinical trials and prototype development.
Carb-X is listed in the NovaPharmaNews Supplier Hub as a CRO & Clinical Services, Diagnostics & Testing partner serving United States & Americas. Core focus areas include antibiotic development, drug-resistant bacteria, antimicrobial resistance, diagnostic accelerator, biotech funding.
Industry categories: CRO & Clinical Services, Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://carb-x.org
- Categories
- CRO & Clinical Services, Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- antibiotic development, drug-resistant bacteria, antimicrobial resistance, diagnostic accelerator, biotech funding
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What types of antibacterial products does CARB-X support?
- CARB-X supports the development of new antibiotics, preventatives, rapid diagnostics, and other products to prevent, diagnose, and treat life-threatening bacterial infections caused by drug-resistant bacteria. The organization supports therapeutics and preventatives from early development stages through Phase 1 clinical trials, and diagnostics from feasibility through prototype development.
- What support does CARB-X provide beyond funding?
- Beyond non-dilutive funding, CARB-X provides comprehensive support including scientific expertise, regulatory guidance, and business advisory services. The organization connects developers with expert advisors, subject matter experts across multiple disciplines, and facilitates market-shaping support to ensure products reach target markets, including low- and middle-income countries.
- What is CARB-X's focus in terms of bacterial targets?
- CARB-X focuses on the most serious drug-resistant bacteria and syndromes with the highest degrees of mortality and morbidity globally. Recent funding priorities include novel chemistry approaches against known antimicrobial resistance targets to unlock innovative starting points for therapeutics addressing dangerous drug-resistant bacterial infections.
- How does CARB-X support early-stage research?
- CARB-X created Portfolio Acceleration Tools to help developers improve predictive models and compare compound toxicity. The organization publishes its methodologies so researchers worldwide can use them in different laboratories to demonstrate proof-of-concept for new antibacterial candidates.
Related editorial coverage
- APHL 2026 Annual: Day 1 Key Takeaways
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
